Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes

Immunology

Volumn 132, Issue 4, 2011, Pages 503-515

  Korniejewska, Anna ^a   Mcknight, Andrew J ^b   Johnson, Zoë ^b   Watson, Malcolm L ^a   Ward, Stephen G ^a  

^a University of Bath   (United Kingdom)

^b UCB Group   (United Kingdom)

Author keywords

Chemokine receptors; Inflammation; Signal transduction; T cells

Indexed keywords

ALPHA CHEMOKINE; CALCIUM ION; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL4 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL MIGRATION; CELL SURFACE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TIME;

ACETAMIDES; BLOTTING, WESTERN; CALCIUM; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINE CXCL9; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GENETIC VARIATION; HEK293 CELLS; HUMANS; PERTUSSIS TOXIN; PHOSPHORYLATION; PLATELET FACTOR 4; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RECEPTORS, CXCR3; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 79952537603     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2010.03384.x     Document Type: Article

References (60)

1. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338:436-45.
2. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001; 2:123-8.
3. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000; 18:593-620.
4. von Andrian UH, Mackay CR. Advances in immunology: T-cell function and migration - two sides of the same coin. N Engl J Med 2000; 343:1020-33.
5. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121-7.
6. Cole KE, Strick CA, Paradis TJ et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187:2009-21.
7. Colvin RA, Campanella GSV, Sun JT, Luster AD. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 2004; 279:30219-27.
8. Cox MA, Jenh CH, Gonsiorek W et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell α chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 2001; 59:707-15.
9. Amichay D, Gazzinelli RT, Karupiah G, Moench TR, Sher A, Farber JM. Genes for chemokines MuMig and Crg-2 induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo. J Immunol 1996; 157:4511-20.
10. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168:3195-204.
11. Khan IA, MacLean JA, Lee FS et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000; 12:483-94.
12. Widney DP, Xia YR, Lusis AJ, Smith JB. The murine chemokine CXCL11 (IFN-inducible T cell α chemoattractant) is an IFN-γ- and lipopolysaccharide-inducible glucocorticoid-attenuated response gene expressed in lung and other tissues during endotoxemia. J Immunol 2000; 164:6322-31.
13. Loetscher M, Gerber B, Loetscher P et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184:963-9.
14. Loetscher M, Loetscher P, Brass N, Meese E, Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 1998; 28:3696-705.
15. Qin SX, Rottman JB, Myers P et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101:746-54.
16. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95:627-32.
17. Muehlinghaus G, Cigliano L, Huehn S et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105:3965-71.
18. Trentin L, Agostini C, Facco M et al. The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J Clin Invest 1999; 104:115-21.
19. Brightling CE, Ammit AJ, Kaur D et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am J Respir Crit Care Med 2005; 171:1103-8.
20. Brightling CE, Kaur D, Berger P, Morgan AJ, Wardlaw AJ, Bradding P. Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration. J Leukoc Biol 2005; 77:759-66.
21. + hemopoietic progenitors induced by granulocyte-macrophage colony-stimulating factor: II. Signaling pathways involved. J Immunol 2001; 167:4405-13.
22. Bonacchi A, Romagnani P, Romanelli RG et al. Signal transduction by the chemokine receptor CXCR3 - activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001; 276:9945-54.
23. Palmqvist C, Wardlaw AJ, Bradding P. Chemokines and their receptors as potential targets for the treatment of asthma. Br J Pharmacol 2007; 151:725-36.
24. Wang XK, Yue TL, Ohlstein EH, Sung CP, Feuerstein GZ. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. J Biol Chem 1996; 271:24286-93.
25. Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 1999; 162:3840-50.
26. Smit MJ, Verdijk P, van der Raaij-Helmer E et al. CXCR3-mediated chemotaxis of human T cells is regulated by a G(i)- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood 2003; 102:1959-65.
27. Dar WA, Knechtle SJ. CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. Immunology 2007; 120:467-85.
28. Mach F, Sauty A, Iarossi AS et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999; 104:1041-50.
29. Sorensen TL, Tani M, Jensen J et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103:807-15.
30. Hancock WW, Lu B, Gao W et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192:1515-9.
31. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193:975-80.
32. Liu MT, Chen BP, Oertel P et al. Cutting edge: the T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 2000; 165:2327-30.
33. Lasagni L, Francalanci M, Annunziato F et al. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197:1537-49.
34. Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 2004; 173:6234-40.
35. Burns JM, Summers BC, Wang Y et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203:2201-13.
36. Balabanian K, Lagane B, Infantino S et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005; 280:35760-6.
37. Coopman K, Smith L, Wright KL, Ward SG. Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharmacol 2007; 7:360-71.
38. Smith LD, Hickman ES, Parry RV, Westwick J, Ward SG. PI3K γ is the dominant isoform involved in migratory responses of human T lymphocytes: effects of ex vivo maintenance and limitations of non-viral delivery of siRNA. Cell Signal 2007; 19:2528-39.
39. Webb A, Johnson A, Fortunato M et al. Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists. J Leukoc Biol 2008; 84:1202-12.
40. Mueller A, Meiser A, McDonagh EM et al. CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol 2008; 83:875-82.
41. Aragay AM, Ruiz-Gomez A, Penela P et al. G protein-coupled receptor kinase 2 (GRK2): mechanisms of regulation and physiological functions. FEBS Lett 1998; 430:37-40.
42. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-Inducible T cell α chemoattractant (CXCL11). J Immunol 2001; 167:7084-93.
43. Heise CE, Pahuja A, Hudson SC et al. Pharmacological characterization of CXC chemokine receptor 3 (CXCR3) ligands and a small-molecule antagonist. FASEB J 2005; 19:A1415.
44. Johnson M, Li AR, Liu JW et al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg Med Chem Lett 2007; 17:3339-43.
45. Proost P, Mortier A, Loos T et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007; 110:37-44.
46. Fleischer J, Grage-Griebenow E, Kasper B et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002; 169:770-7.
47. Romagnani P, Maggi L, Mazzinghi B et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on Th1 or Th2 cytokine production. J Allergy Clin Immunol 2005; 116:1372-9.
48. - (nonregulatory) T cells. J Immunol 2005; 174:2680-6.
49. -/- mice. Thromb Haemost 2007; 98:1108-13.
50. Pitsilos S, Hunt J, Mohler ER et al. Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003; 90:1112-20.
51. Richardson RM, Pridgen BC, Haribabu B, Ali H, Snyderman R. Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2 - evidence for time-dependent signal generation. J Biol Chem 1998; 273:23830-6.
52. Fan GH, Yang W, Wang XJ, Qian QH, Richmond A. Identification of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding and receptor internalization. Biochemistry 2001; 40:791-800.
53. Benbaruch A, Bengali KM, Biragyn A et al. Interleukin-8 receptor-β- the role of the carboxyl-terminus in signal-transduction. J Biol Chem 1995; 270:9121-8.
54. Yang W, Wang DZ, Richmond A. Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization, and signal transduction. J Biol Chem 1999; 274:11328-33.
55. Richardson RM, Marjoram RJ, Barak LS, Snyderman R. Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J Immunol 2003; 170:2904-11.
56. Vroon A, Heijnen CJ, Kavelaars A. GRKs and arrestins: regulators of migration and inflammation. J Leukoc Biol 2006; 80:1214-21.
57. Cole SW, Jamieson BD, Zack JA. cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection. J Immunol 1999; 162:1392-400.
58. Arai H, Monteclaro FS, Tsou CL, Franci C, Charo IF. Dissociation of chemotaxis from agonist-induced receptor internalization in a lymphocyte cell line transfected with CCR2B - evidence that directed migration does not require rapid modulation of signaling at the receptor level. J Biol Chem 1997; 272:25037-42.
59. Kenakin T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 2007; 28:407-15.
60. Baker JG, Hill SJ. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 2007; 28:374-81.